{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=69", "query": { "intervention": "Cellular analysis", "page": 69 }, "page_size": 10 }, "pagination": { "page": 69, "page_size": 10, "total_count": 2010, "total_pages": 201, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=70&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=68&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T17:23:06.838Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01168219", "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Alkylating Agent-Related Acute Myeloid Leukemia", "de Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 68, "start_date": "2010-07-15", "completion_date": "2020-02-01", "has_results": true, "last_update_posted_date": "2022-08-04", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 17, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01168219" }, { "nct_id": "NCT00087373", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087373" }, { "nct_id": "NCT06399419", "title": "CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Advanced Sarcomatoid Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "CBM588 Capsules", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Osel, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2024-06-19", "completion_date": "2026-10-19", "has_results": false, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06399419" }, { "nct_id": "NCT04226131", "title": "MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis", "Healthy Controls" ], "interventions": [ { "name": "Blood Draw", "type": "OTHER" }, { "name": "Disease Activity (DAS-28) Assessment", "type": "OTHER" }, { "name": "Skeletal Muscle Mitochondrial Respiratory Capacity", "type": "OTHER" }, { "name": "Muscle Biopsy", "type": "OTHER" }, { "name": "Body Composition", "type": "OTHER" }, { "name": "Cardiopulmonary Exercise Test (CPET)", "type": "OTHER" }, { "name": "Strength Testing", "type": "OTHER" }, { "name": "Questionnaires", "type": "OTHER" }, { "name": "Skeletal Muscle Biomechanical Property Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "25 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2020-09-09", "completion_date": "2023-07-07", "has_results": false, "last_update_posted_date": "2023-07-13", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04226131" }, { "nct_id": "NCT02506153", "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Non-Cutaneous Melanoma", "Non-Cutaneous Melanoma", "Recurrent Cutaneous Melanoma", "Recurrent Mucosal Melanoma", "Recurrent Non-Cutaneous Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1301, "start_date": "2015-11-10", "completion_date": "2027-01-23", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 552, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506153" }, { "nct_id": "NCT02728700", "title": "Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Hodgkin Lymphoma", "Adult Myelodysplastic Syndrome", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Childhood Hodgkin Lymphoma", "Childhood Myelodysplastic Syndrome", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Myelofibrosis", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "3 Years to 30 Years" }, "enrollment_count": 1, "start_date": "2016-02", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728700" }, { "nct_id": "NCT03226249", "title": "PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma", "Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Lymphocyte-Rich Classical Hodgkin Lymphoma", "Mixed Cellularity Classical Hodgkin Lymphoma", "Nodular Sclerosis Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Vinblastine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-11-09", "completion_date": "2024-10", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 4, "location_summary": "Stanford, California • Atlanta, Georgia • Chicago, Illinois + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03226249" }, { "nct_id": "NCT00228358", "title": "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor" ], "interventions": [ { "name": "ex vivo-expanded HER2-specific T cells", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "denileukin diftitox", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-11", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228358" }, { "nct_id": "NCT03360708", "title": "Vaccine Therapy in Treating Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Giant Cell Glioblastoma", "Recurrent Glioblastoma", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-11-27", "completion_date": "2021-06-02", "has_results": false, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03360708" }, { "nct_id": "NCT03384407", "title": "Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Red Cell Survival in Healthy Volunteers" ], "interventions": [ { "name": "Red cell survival in INTERCEPT treated red cells", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-01-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2019-01-09", "last_synced_at": "2026-11-07T17:23:06.838Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384407" } ] }